P018 Updates in Oncodermatology
DESCRIPTION
This session will be directed towards general dermatologists wanting more familiarity with oncodermatology. It will involve updates on therapy toxicities for patients on immunotherapy, EGFR inhibitors, enfortumab vedotin and combination regimens. There will also be a section on melanoma updates and oncodermatology considerations for patients post stem cell transplantation. Attendants will gain a better understanding of critical updates in these key areas of oncodermatology which will strengthen clinical practice. Learners will take away practical diagnostic and treatment approaches for common clinical scenarios in oncodermatology. Teaching will be substantiated with representative cases as well as relevant literature.
LEARNING OBJECTIVES
Describe, diagnose, and manage the cutaneous adverse events that occur in patients on immunotherapy, EGFR inhibitors, and enfortumab vedotin
Discuss important updates in the diagnosis and management options of patients with advanced melanoma
Identify and treat the unique skin conditions relevant to patients with hematologic malignancies
SCHEDULE
6:00 PM
Introduction to Session
Meghan M. Heberton, MD, FAAD
6:05 PM
Updates in Immune Checkpoint Inhibitor Therapy Cutaneous Toxicities
Brittany L Dulmage, MD, FAAD
6:25 PM
Updates in EGFR Inhibitor Therapy Cutaneous Toxicities
Fiorinda Fiona Muhaj, MD, FAAD
6:45 PM
Novel challenges: Enfortumab Vedotin and Combination Regimens
Meghan M. Heberton, MD, FAAD
7:00 PM
Questions: Therapy Toxicities
7:10 PM
Updates in Melanoma
Jennifer Gibson Gill, MD, PhD, FAAD
7:30 PM
Questions
7:35 PM
Cutaneous Considerations after Hematopoietic Stem Cell Transplantation
Connie Shi, MD, FAAD
7:55 PM
Questions
SPEAKERS
Brittany L Dulmage, MD, FAAD
Department of Dermatology, Ohio State University Wexner Medical Center
Jennifer Gibson Gill, MD, PhD, FAAD
University of Texas Southwestern Medical Center
Meghan M. Heberton, MD, FAAD
UT Southwestern Medical Center
Fiorinda Fiona Muhaj, MD, FAAD
Connie Shi, MD, FAAD
SPEAKER DISCLOSURES
Brittany L Dulmage, MD, FAAD
Azitra, Inc – Investigator(Grants/Research Funding); Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Fees);
Jennifer Gibson Gill, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Meghan M. Heberton, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Blueprint Medicines – Advisory Board(Fees);
Fiorinda Fiona Muhaj, MD, FAAD
No financial relationships exist with ineligible companies.
Connie Shi, MD, FAAD
No financial relationships exist with ineligible companies.